Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study

Abstract The prospective 1-year EPIC study enrolled 341 patients with myelodysplastic syndromes (MDS); although baseline iron burden was >2500 ng/mL, ∼50% were chelation-naïve. Overall median serum ferritin decreased significantly at 1 year ( p = 0.002). Decreases occurred irrespective of whether...

Full description

Saved in:
Bibliographic Details
Published in:Leukemia research 2010-09, Vol.34 (9), p.1143-1150
Main Authors: Gattermann, Norbert, Finelli, Carlo, Porta, Matteo Della, Fenaux, Pierre, Ganser, Arnold, Guerci-Bresler, Agnes, Schmid, Mathias, Taylor, Kerry, Vassilieff, Dominique, Habr, Dany, Domokos, Gabor, Roubert, Bernard, Rose, Christian
Format: Article
Language:English
Subjects:
Adolescent
Adult
Aged
Alanine Transaminase - blood
Benzoates - adverse effects
Benzoates - therapeutic use
Blood Transfusion
Child
Child, Preschool
Deferasirox
Female
Ferritins - blood
Hematology, Oncology and Palliative Medicine
Humans
Iron Chelating Agents - adverse effects
Iron Chelating Agents - therapeutic use
Iron chelation therapy
Iron Overload - complications
Iron Overload - drug therapy
Labile plasma iron
Male
Middle Aged
Myelodysplastic syndromes
Myelodysplastic Syndromes - complications
Serum ferritin
Triazoles - adverse effects
Triazoles - therapeutic use
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract The prospective 1-year EPIC study enrolled 341 patients with myelodysplastic syndromes (MDS); although baseline iron burden was >2500 ng/mL, ∼50% were chelation-naïve. Overall median serum ferritin decreased significantly at 1 year ( p = 0.002). Decreases occurred irrespective of whether patients were chelation-naïve or previously chelated; changes were dependent on dose adjustments and ongoing iron intake. Sustained reductions in labile plasma iron were observed. Discontinuation rate (48.7%) and adverse event profile were consistent with previously reported deferasirox data in MDS. Alanine aminotransferase levels decreased significantly; change correlated significantly with reduction in serum ferritin ( p < 0.0001). This large dataset prospectively confirms the efficacy and well characterizes the safety profile of deferasirox in MDS.
ISSN:0145-2126
1873-5835
DOI:10.1016/j.leukres.2010.03.009